Result - Financial Results
- Q1 FY27 total revenue grew 166% YoY to ₹7.57 Cr, delivering ~39% of entire FY26 revenue in a single quarter.
- Trailing 12-month EPS improved to ₹1.25 post Q1 FY27 (from ₹0.83 in FY26), lowering trailing P/E to ~19.3x.
- Manageable debt profile with D/E at 0.25 (Debt ₹2 Cr vs Net Worth ₹10 Cr).
- Promoter holding increased incrementally over recent quarters from 26.38% to 27.82%.
- Promoter holding is very low at 27.82%, well below the 35% safety threshold.
- Sharp margin contraction: Q1 FY27 Net Margin fell to 2.9% due to a spike in 'Other Expenses' to ₹1.86 Cr vs ₹0.38 Cr in Q4 FY26.
- Sub-par return ratios with ROCE at 7.2% and trailing NPM at 2.18%.
- Micro-cap illiquidity and execution risk on sustaining higher quarterly scale.
- Promoter holding is critically low at 27.82% (< 35% safe limit).
Executive Summary
Beryl Drugs reported strong Q1 FY27 top-line expansion, with revenue surging 166% YoY to ₹7.57 Cr, accounting for nearly 40% of its full-year FY26 top-line. However, bottom-line profitability remains muted due to a disproportionate surge in 'Other Expenses' (₹1.86 Cr vs ₹0.38 Cr in Q4 FY26), restricting Q1 PAT to ₹0.22 Cr. Furthermore, the company suffers from weak underlying quality metrics (ROCE 7.2%) and low promoter holding (27.82%). Per strict methodology rules, promoter holding below 35% caps the multibagger verdict at POSSIBLE and confidence at <= 0.50.
Financial & Ramp Math
- TTM Revenue Run-rate: Prior TTM revenue was ₹19.31 Cr. Adding Q1 FY27 (₹7.57 Cr) and dropping Q1 FY26 (₹2.84 Cr) brings TTM revenue to ₹22.05 Cr (+14.2% TTM expansion).
- Annualized Q1 Run-rate: If Q1 FY27 top-line (₹7.57 Cr) is sustained, annual revenue would reach ~₹30.28 Cr (+56.8% over FY26).
- Earnings Impact: Q1 FY27 EPS came in at ₹0.47. Trailing 4-quarter EPS (Q2 FY26-Q1 FY27) stands at ₹1.25 (0.02 + -0.34 + 1.10 + 0.47). At current price ₹24.1, trailing P/E adjusts down to 19.3x from 29.4x.
- Margin Drag: Despite revenue surging to ₹7.57 Cr, net profit margin dropped to 2.9% in Q1 FY27. This margin weakness tempers the EPS conversion from top-line growth.
Quality & Governance Assessment
- Quality Gate: FAILED. ROCE is 7.2% vs >15% standard threshold.
- Promoter Holding: 27.82% (Jun 2026). This low skin-in-the-game poses equity overhang and governance risk, binding the final score.
- Balance Sheet: Debt of ₹2 Cr vs Equity of ₹10 Cr (D/E 0.25) is reasonably safe.
Valuation & Scenario Analysis
- Base Case (+25% / ₹30.1): Revenue ramps to ~₹26 Cr in FY27 with normalized net margins of 4%, generating PAT of ₹1.04 Cr (EPS ₹2.05). Valued at 15x P/E.
- Bull Case (+60% / ₹38.5): Revenue run-rate of ₹30 Cr sustained with margin expansion to 5.5% (PAT ₹1.65 Cr, EPS ₹3.25) as operating leverage kicks in. Valued at 12x P/E.
- Bear Case (-30% / ₹16.8): Revenue growth normalizes back to ₹20 Cr and higher 'Other Expenses' persist, depressing annual PAT to ₹0.35 Cr (EPS ₹0.70). De-rates to 24x P/E.
Conclusion & Verdict Rationale
While Q1 FY27 demonstrates genuine top-line traction, poor margin quality and low promoter ownership (27.82%) prevent a STRONG_CANDIDATE classification. The stock is rated POSSIBLE with a confidence score of 0.50.
